Moreover, before PSM, there was significant heterogeneity in baseline data between the two groups, such as gender, AFP, tumor size, MVI, satellite foci, tumor number, and tumor envelope, which may be significantly different from the inclusion criteria of the two groups at the beginning of treatment. The gene discussed is AFP; the disease is neoplasm.